Evogene posts $3.5 million revenue and $8.8 million operating loss for first nine months of 2025

Evogene Ltd. reported third quarter 2025 financial results, highlighting a total operating loss of $8.8 million for the first nine months of 2025, down from $15.3 million in the same period of 2024. Revenues for the nine months ending September 30, 2025, were $3.5 million, compared to $4.0 million in the previous year, mainly due to lower revenue from AgPlenus and a one-time payment from Bayer in 2024, partially offset by increased seed sales from Casterra. Total operating expenses for the third quarter were approximately $2.9 million, down from $6.6 million in Q3 2024. As of September 30, 2025, cash and short-term bank deposits stood at $16.0 million, reflecting proceeds from the sale of Lavie Bio’s assets and MicroBoost AI for Ag to ICL. The sale of these assets generated net income of approximately $7.9 million in the third quarter. The company has realigned its organization and reduced costs as part of a strategic shift towards computational chemistry and the generative design of small molecules for pharmaceutical and agricultural industries. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003915), on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here